DDR1 and neoplasm: We next addressed the in vivo relevance of our model by investigating the effect of DDR1 activity on the oncogenic level of β‐catenin in liver metastatic tumours obtained in Fig 3F. Immunohistochemistry staining of liver sections shows that DDR1 expression significantly increases the level of nuclear and active β‐catenin in CRC cells, specifically at the front of the tumour, while nilotinib treatment significantly reduces this molecular response (Figs EV4C and 6F).